北陆药业：碘美普尔化学原料药获批上市

Core Viewpoint - Beilu Pharmaceutical (300016.SZ) announced that its subsidiary, Zhejiang Haichang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the marketing application of Iopamidol [1] Group 1: Product Information - Iopamidol is a raw material for the contrast agent Iopamidol injection, characterized as a low-osmolar, non-ionic, water-soluble contrast agent [1] - Iopamidol injection is widely used in CT enhancement imaging and vascular imaging [1] - Compared to traditional high-osmolar contrast agents, Iopamidol places a lower burden on patients' kidneys and cardiovascular systems, making it particularly suitable for patients with renal impairment and those at high risk [1] Group 2: Clinical Significance - Due to its excellent imaging effects and lower side effects, Iopamidol has become one of the preferred contrast agents in clinical settings [1]